VEGFA and non-small cell lung carcinoma: Another study investigated the prognostic and predictive value of baseline and post-treatment levels of serum VEGF-A, VEGF-B, sPD-1, and sPD-L1 of advanced NSCLC patients treated with immune checkpoint inhibitors.